Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
| Revenue (TTM) | $24.00M |
| Gross Profit (TTM) | $-99.98M |
| EBITDA | $-141.65M |
| Operating Margin | -308.70% |
| Return on Equity | -10.70% |
| Return on Assets | -8.80% |
| Revenue/Share (TTM) | $0.38 |
| Book Value | $15.19 |
| Price-to-Book | 1.09 |
| Price-to-Sales (TTM) | 41.52 |
| EV/Revenue | 2.502 |
| EV/EBITDA | -33.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2178.00% |
| Shares Outstanding | $61.14M |
| Float | $42.53M |
| % Insiders | 1.49% |
| % Institutions | 101.29% |
Volatility is currently contracting
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC). The program is initially being developed in combination with JANX007, with the goal of furthe.
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Undercovered Dozen series spotlights 12 lesser-covered stocks from the past week on Seeking Alpha. This week's edition covers articles published between April 24 and April 30, offering fresh investment ideas. The focus is on stocks that may offer unique opportunities due to limited analyst coverage.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal revie.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on JANX and any ticker you trade — then tracks every position and per-strategy win rate.
